|
|
Article: Biomoda Prepares for Phase III Clinical Trials.
- Article from:
- Cancer Weekly
- Article date:
- November 10, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Medical diagnostics company Biomoda, Inc. (OTCBB: BMOD) is taking preliminary steps to launch multisite Phase III clinical trials of its in-vitro diagnostic for early-stage lung cancer, trademarked under the name CyPath[R] (see also Biomoda, Inc.).
"As the Phase II trial wraps up, we are making sure that all the pieces are in place to move immediately to a nationwide Phase III," Biomoda President John Cousins said. "Most significantly, Dr. Thomas Bauer, the Principal Investigator (PI) overseeing Phase II, has agreed to continue in the same role for our Phase III trials. Dr. Bauer is widely recognized as one of the top lung cancer researchers in the field, and we ...